Novartis has secured U.S. Food and Drug Administration approval for Rhapsido, or remibrutinib, as the first treatment specifically indicated for adults with symptomatic dermographism whose disease remains inadequately controlled by H1 antihistamines. The approval expands the oral Bruton’s tyrosine kinase inhibitor beyond chronic spontaneous urticaria and gives Novartis the only prescription medicine currently approved for both of the most common forms of chronic hives in adults who remain symptomatic despite antihistamine therapy.
The decision is supported by the Phase III RemIND trial, where 29.3% of patients receiving Rhapsido achieved complete resolution of hives by Week 12 compared with 14.0% receiving placebo. Responses were observed as early as Week 2, while the safety profile remained consistent with the drug’s established use in chronic spontaneous urticaria.
Phase III RemIND data showed twice as many patients achieved complete hive resolution
Symptomatic dermographism is the most common form of chronic inducible urticaria, in which relatively ordinary physical contact with the skin can trigger wheals and itching. Scratching, rubbing, pressure from clothing or other friction can provoke symptoms, creating a persistent burden that may interfere with sleep, work and normal daily activity.
The RemIND study enrolled adults whose symptomatic dermographism remained inadequately controlled despite second-generation H1 antihistamines. Rhapsido significantly increased the proportion of patients who achieved complete resolution of hives on the Total Fric Score, the study’s disease-specific assessment. At Week 12, complete response was reported in 29.3% of patients receiving remibrutinib compared with 14.0% receiving placebo, with a p-value of 0.0229.
The absolute difference was approximately 15 percentage points, meaning the result is clinically relevant but should not be interpreted as showing that most treated patients became completely symptom-free. Roughly seven in 10 patients did not reach complete hive resolution by Week 12, so the approval provides an additional treatment option rather than a universal solution for symptomatic dermographism.
The early onset of response is another potentially important feature. Novartis reported that clinical improvement was detectable from Week 2, which could matter for patients who have persistent symptoms despite continued antihistamine therapy. Longer-term response durability and the proportion achieving partial rather than complete control will also help determine how the treatment is used in routine practice.
Rhapsido expands treatment beyond antihistamines with an oral BTK-targeting mechanism
Rhapsido is a highly selective oral inhibitor of Bruton’s tyrosine kinase, commonly known as BTK. The pathway plays an important role in signaling within immune cells involved in histamine release and other inflammatory responses that contribute to hives, swelling and itching.
By inhibiting BTK, remibrutinib is intended to interrupt that signaling upstream rather than simply blocking histamine after it has already been released. This creates a mechanistically different option from H1 antihistamines, which remain the initial treatment for most patients with chronic urticaria.
The distinction is relevant because more than half of patients with chronic inducible urticaria remain symptomatic despite H1 antihistamine treatment, according to evidence cited by Novartis. Symptomatic dermographism is also the most prevalent form of chronic inducible urticaria, making it one of the larger patient groups within a disease category that has historically had few therapies developed specifically for it.
Rhapsido is taken orally and does not require routine laboratory monitoring, a feature Novartis has also emphasized in chronic spontaneous urticaria. That could simplify treatment compared with therapies requiring injections or regular laboratory surveillance, although prescribing decisions will still depend on individual safety considerations, comorbidities and response to antihistamines.
Safety profile remained consistent with established Rhapsido experience
The symptomatic dermographism safety findings were broadly consistent with the profile already observed in chronic spontaneous urticaria. Across clinical trials through Week 24, the most commonly reported adverse events occurring in at least 3% of patients included nasopharyngitis, bleeding events, headache, nausea and abdominal pain.
The absence of a new major safety signal is important because Rhapsido already has clinical exposure from its first U.S. indication. FDA approval in chronic spontaneous urticaria established a regulatory safety framework that Novartis can now extend into a second chronic-hives population.
BTK inhibitors as a class have historically attracted attention for bleeding, infection and liver-related risks, although safety profiles differ substantially depending on selectivity, dosing and therapeutic setting. Novartis has repeatedly emphasized that remibrutinib has shown no liver-safety signal requiring routine laboratory monitoring in its urticaria development program.
The symptomatic dermographism approval therefore strengthens the case that selective BTK inhibition can be used chronically in an allergy and immunology setting rather than being restricted to the oncology applications where the drug class was first established.
Second U.S. hives indication strengthens Novartis’ broader remibrutinib development strategy
Rhapsido was initially approved in the United States for adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines. That earlier approval gave Novartis an oral targeted therapy in a market where patients often cycle through antihistamines and injectable biologics when symptoms remain uncontrolled.
The symptomatic dermographism expansion now gives the same molecule approved indications in the two forms of chronic hives responsible for the large majority of cases seen among adults. Novartis said more than 90% of adults with chronic hives experience either chronic spontaneous urticaria or symptomatic dermographism.
The company is also evaluating remibrutinib in additional forms of chronic inducible urticaria, including cold urticaria and cholinergic urticaria. The full RemIND dataset includes those cohorts, and Novartis plans to submit results to regulators where appropriate.
That creates the possibility of building a broader urticaria franchise around a single oral medicine rather than limiting remibrutinib to one subtype. Whether those additional populations ultimately support approvals will depend on the strength and consistency of the remaining RemIND results.
Multiple sclerosis program could become much larger than the current urticaria opportunity
The larger long-term significance of remibrutinib may eventually extend far beyond allergy and dermatology. Novartis recently reported positive topline results from the Phase III REMODEL-1 and REMODEL-2 studies in relapsing multiple sclerosis, where the drug produced clinically meaningful reductions in annualized relapse rates and delayed disability progression compared with teriflunomide.
That program is especially important because multiple sclerosis represents a much larger commercial opportunity than symptomatic dermographism. The same highly selective BTK inhibitor is therefore being developed across immunology and neuroscience, giving Novartis several potential routes to expand the molecule’s clinical and commercial reach.
Remibrutinib is also being studied in hidradenitis suppurativa and food allergy. Novartis previously reported positive Phase II evidence in IgE-mediated peanut allergy and has been advancing a Phase III development program in food allergy, further testing whether BTK inhibition can be applied across diseases driven by abnormal immune-cell activation.
The growing list of indications makes the symptomatic dermographism approval more significant than a single label extension. Each additional successful indication provides more clinical experience with the drug and helps determine whether remibrutinib can become a broad immunology platform medicine rather than a niche chronic-hives therapy.
FDA approval creates a new option but complete symptom control remains difficult
Rhapsido’s first-in-indication status addresses a genuine treatment gap, particularly for patients whose hives are repeatedly triggered by unavoidable friction or pressure and remain uncontrolled despite antihistamines. The oral route and absence of routine laboratory monitoring could also make the treatment practical for long-term outpatient use.
The Phase III numbers nevertheless show that symptomatic dermographism remains difficult to treat completely. Fewer than one-third of Rhapsido-treated patients achieved total hive resolution at Week 12, meaning clinicians and patients should expect variable degrees of response rather than assuming complete symptom elimination. Additional data on itch, quality of life, partial response and longer-term durability will therefore be important when comparing the treatment’s clinical value with off-label approaches currently used in more difficult cases.
For Novartis, the approval expands Rhapsido into a second U.S. market while the company simultaneously advances the molecule into substantially larger immune and neurological indications. For patients with symptomatic dermographism, the immediate significance is simpler: there is now an FDA-approved treatment developed specifically for a condition that until now relied largely on antihistamines and therapies borrowed from other forms of chronic urticaria.
